Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 4
Submit an article Journal homepage
1,063
Views
38
CrossRef citations to date
0
Altmetric
Research Article

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

G. DamajUniversity Hospital, Hematology, Amiens, France
,
F. MalardUniversity Hospital, Hematology, Place Alexis Ricordeau, Nantes, France
,
C. HulinUniversity Hospital, Hematology, Nancy, France
,
D. CaillotUniversity Hospital, Hematology, Dijon, France
,
R. GaridiCentre Hospitalier, Hematology, Saint Quentin, France
,
B. RoyerUniversity Hospital, Hematology, Amiens, France
,
G. MaritUniversity Hospital, Hematology, Bordeaux, France
,
A.M. StoppaInstitut Paoli Calmettes, Hematologie, Marseille, France
,
A. BanosCentre Hospitalier, Hématologie, Bayonne, France
,
N. Morineauclinique Catherine De Sienne, Hematologie, Nantes, France
,
P. MoreauCentre hospitalier, hematology, Lorient, France
,
O. FitoussiPolyclinique Bordeaux Nord, hematology, Bordeaux, France
,
M. TiabCentre Hospitalier, Hematology, La Roche Sur Yon, France
&
P. MoreauCHU Hôtel-Dieu, Hematology Department, Place Ricordeau, Nantes, FranceCorrespondence[email protected]
 show all
Pages 632-634 | Received 18 Jul 2011, Accepted 06 Sep 2011, Published online: 27 Apr 2012

References

  • Kumar SK, Rajkumar SV, Dispenzieri A, . Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.
  • Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2010;2010:303–309.
  • Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492–1501.
  • Strumberg D, Harstrick A, Doll K, . Bendamustine hydrochloride activity against doxorubicinresistant human breast carcinoma cell lines. Anticancer Drugs 1996;7:415–421.
  • Leoni LM, Bailey B, Reifert J, . Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309–317.
  • Bladé J, Samson D, Reece D, . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
  • Knop S, Straka C, Haen M, . The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287–1288.
  • Pönisch W, Rozanski M, Goldschmidt H, . Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol 2008;143:191–200.
  • Fenk R, Michael M, Zohren F, . Escalation therapy with bortezomib, dexamethasone, and bendamustine for patients with relapsed or refractory myeloma. Leuk Lymphoma 2007;48: 2345–2351.
  • Schey S, Ramasamy K, Hazel B, . Bendamustine is a well tolerated and effective therapy for multiple myeloma patients with renal impairment. Haematologica 2011;96(s1):S115 (P-285).
  • Cheson BD, Wendtner CM, Pieper A, . Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21–27.
  • Lacy MQ, Hayman SR, Gertz MA, . Pomalidomide and low-dose dexamethasone is active and well tolerated in lenalidomide refractory multiple myeloma. Leukemia 2010;24:1934–1939.
  • Siegel D, Wang L, Orlowski RZ, . PX-171–004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood (ASH Annual Meeting Abstracts) 2009;114:303.
  • Kumar S, Blade J, Crowley J, . Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Blood (ASH Annual Meeting Abstracts) 2009;114:2878.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.